Conference Coverage
Videos
NewsNetwork
OncLive® TV
Peer Exchange
Insights
Attend An Event
State of the Science Summit
Regional Seminar Series
PER Conferences
Giants of Cancer Care
ISGIO
Webinars
OncLive Community
SPECIALTY TOPICS
CURRENTLY VIEWING
All Specialties
Breast Cancer
Multiple Myeloma
Lung Cancer
Immuno-Oncology News
Gynecologic Oncology
Gastrointestinal Cancer
Colorectal Cancer
Ovarian Cancer
Prostate Cancer
Precision Medicine in Oncology®
Neoadjuvant HER2+
More >>
Related Articles
ASTRO Presents First Guideline for RT in Pancreatic Cancer
FDA Grants Priority Review to Pemigatinib for FGFR2+ Cholangiocarcinoma
Atezolizumab Plus Bevacizumab Extends Survival in Frontline HCC
Related Videos
Dr. Catenacci on Treatment Selection in Esophagogastric Junction Adenocarcinoma
Dr. Shah on Improving the Benefit of Immunotherapy in Gastric/GEJ Cancer
Dr. Hidalgo Medina on Treatment Considerations in Pancreatic Cancer
News >

Avelumab Falls Short as Frontline Maintenance for Gastric/GEJ Cancer

Jason M. Broderick @jasoncology
Published: Friday, Nov 08, 2019

Markus Mohler, MD, PhD, head of GI Oncology, senior physician Gastroenterology & Endosonography, Johannes-Gutenberg University, Mainz, Germany

Markus Möhler, MD, PhD

Avelumab (Bavencio) did not improve overall survival (OS) as frontline maintenance following induction chemotherapy in patients with unresectable, locally advanced, or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) cancer, according to topline results from the phase III JAVELIN Gastric 100 study.1

Grade ≥3 treatment-related AEs occurred in 9.2% of the avelumab group compared with 31.6% of the chemotherapy group.

References           

  1. EMD Serono and Pfizer provide update on phase III JAVELIN GASTRIC 100 trial. Pfizer. Published November 8, 2019. https://bit.ly/36IzHpP. Accessed November 8, 2019.  
  2. Bang YJ, Ruiz EY, Van Cutsem E, et al. Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann Oncol. 2018;29(10):2052-2060. doi: 10.1093/annonc/mdy264.

... to read the full story
To Read the Full Story
REGISTER
LOG IN

View Other News on Gastrointestinal Cancer
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
 
x